TRex Bio, Inc.

TRex Bio, Inc. (TRXB) priced its initial public offering on Oct 9, 2026 at $14.00 per share, within its $14.00–$16.00 range, raising $116.7M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $384.2M. J.P. Morgan was lead-left underwriter, joined by Evercore ISI, Cantor and Stifel and others. Latham & Watkins advised the underwriters.

TRex Bio, Inc. is a clinical-stage biopharmaceutical company developing immunoregulatory medicines based on tissue regulatory T cell biology, intended to restore immune balance and promote tissue repair in autoimmune and inflammatory diseases.

Status

IPO

Ticker

TRXB

Exchange

Nasdaq Global Select

Priced

Oct 9, 2026

IPO price

$14.00

Price range

$14.00–$16.00

Raised

$116.7M

Market cap at IPO price

$384.2M

First filed

Sep 18, 2026

Underwriters

J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.